Catabasis Pharmaceuticals, Inc. To Report Third Quarter 2015 Financial Results And Recent Corporate Developments On Thursday, November 12

The Company will Host a Conference Call at 4:30pm ET

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage drug development company built on a pathway pharmacology technology platform, will report third quarter 2015 financial results after the NASDAQ Global Market close on Thursday, November 12, 2015. Jill C. Milne, chief executive officer, and Ian Sanderson, chief financial officer, will host a conference call and webcast at 4:30pm ET to provide an update on corporate developments and to discuss third quarter financial results.

Please specify to the operator that you would like to join the “Catabasis Third Quarter 2015 Results Call.”

Interested parties may access a live audio webcast of the conference call via the investor section of the Catabasis website, www.catabasis.com. Please connect to the Catabasis website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

The conference call will also be available to be replayed for 2 weeks following the call at (855) 859-2056 for domestic callers and (404) 537-3406 for international callers, both with the Pass Code 64559583. The webcast will be archived for 90 days.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company’s focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company’s technology and pipeline of drug candidates, please visit www.catabasis.com.